Matching articles for "Elidel"
Roflumilast Cream (Zoryve) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • September 16, 2024; (Issue 1711)
The FDA has approved a 0.15% cream formulation
of the phosphodiesterase-4 (PDE4) inhibitor
roflumilast (Zoryve – Arcutis) for topical treatment of
mild to moderate atopic dermatitis (AD) in patients
≥6...
The FDA has approved a 0.15% cream formulation
of the phosphodiesterase-4 (PDE4) inhibitor
roflumilast (Zoryve – Arcutis) for topical treatment of
mild to moderate atopic dermatitis (AD) in patients
≥6 years old. Roflumilast is the second PDE4 inhibitor
to be approved in the US for treatment of AD;
crisaborole (Eucrisa), which can be used in patients
≥3 months old, was the first. Roflumilast is available
as Zoryve in a 0.3% cream for treatment of plaque
psoriasis and a 0.3% foam for treatment of seborrheic
dermatitis. It is also available in an oral formulation
(Daliresp) for treatment of chronic obstructive
pulmonary disease.
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics • April 15, 2024; (Issue 1700)
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old....
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old. Roflumilast is
the first PDE4 inhibitor to be approved in the US for
this indication. It is also available in a 0.3% cream
formulation (Zoryve) for treatment of plaque psoriasis
and in an oral formulation (Daliresp, and generics) for
treatment of chronic obstructive pulmonary disease.
A 0.15% cream formulation for treatment of atopic
dermatitis in patients ≥6 years old will be reviewed by
the FDA in July.
Ruxolitinib (Opzelura) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • January 24, 2022; (Issue 1642)
The FDA has approved a 1.5% topical cream
formulation of the Janus kinase (JAK) inhibitor
ruxolitinib (Opzelura – Incyte) for short-term, non-continuous
chronic treatment of mild to moderate
atopic...
The FDA has approved a 1.5% topical cream
formulation of the Janus kinase (JAK) inhibitor
ruxolitinib (Opzelura – Incyte) for short-term, non-continuous
chronic treatment of mild to moderate
atopic dermatitis (AD) in non-immunocompromised
patients ≥12 years old whose disease has not been
adequately controlled with other topical prescription
drugs. Ruxolitinib is the first JAK inhibitor to be
approved for topical use and the first to be approved
in the US for treatment of AD. An oral formulation
of ruxolitinib (Jakafi) is approved for treatment of
myelofibrosis, polycythemia vera, and graft-versus-host
disease.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • June 15, 2020; (Issue 1600)
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Drugs for Psoriasis
The Medical Letter on Drugs and Therapeutics • June 17, 2019; (Issue 1574)
Mild to moderate psoriasis can be treated with topical
drugs or with phototherapy. Patients with moderate to
severe disease generally require systemic...
Mild to moderate psoriasis can be treated with topical
drugs or with phototherapy. Patients with moderate to
severe disease generally require systemic therapy.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human
monoclonal antibody, for treatment of adults with
moderate to severe atopic dermatitis (eczema) that
has...
The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human
monoclonal antibody, for treatment of adults with
moderate to severe atopic dermatitis (eczema) that
has not responded to topical therapies. It can be used
with or without topical corticosteroids.
Crisaborole (Eucrisa) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • February 27, 2017; (Issue 1515)
The FDA has approved crisaborole 2% ointment
(Eucrisa – Pfizer) for topical treatment of mild to
moderate atopic dermatitis in patients ≥2 years old. It
is the first phosphodiesterase type-4 (PDE4)...
The FDA has approved crisaborole 2% ointment
(Eucrisa – Pfizer) for topical treatment of mild to
moderate atopic dermatitis in patients ≥2 years old. It
is the first phosphodiesterase type-4 (PDE4) inhibitor
to be approved in the US for this indication.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 1, 2013; (Issue 129)
The use of drugs to prevent and control symptoms of
allergic disorders can be optimized when patients
avoid exposure to specific allergens and/or environmental
conditions that trigger or worsen their...
The use of drugs to prevent and control symptoms of
allergic disorders can be optimized when patients
avoid exposure to specific allergens and/or environmental
conditions that trigger or worsen their symptoms.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • August 1, 2007; (Issue 60)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.
In Brief: Elidel and Protopic
The Medical Letter on Drugs and Therapeutics • March 28, 2005; (Issue 1205)
The FDA issued a public health advisory on March 10, 2005 warning about a risk of cancer with topical formulations of tacrolimus (Protopic) and pimecrolimus (Elidel) used to treat eczema in adults and children...
The FDA issued a public health advisory on March 10, 2005 warning about a risk of cancer with topical formulations of tacrolimus (Protopic) and pimecrolimus (Elidel) used to treat eczema in adults and children more than 2 years old. Elidel has been heavily promoted to the general public on television. The warning was based on reports of dose-related cancer in animals and 29 reports of cancer (including 8 skin malignancies and 12 lymphomas) in adults and children treated with these immunosuppressive drugs. Cause and effect have not been established. When Protopic was first marketed, The Medical Letter warned that the possibility of an increased risk of skin malignancies and lymphoma should be kept in mind (Med Lett Drugs Ther 2001; 43:33).
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • November 1, 2003; (Issue 15)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence during the past 30 years and are now epidemic worldwide, especially in industrialized countries. Many safe and effective drugs are currently available for prevention and relief of symptoms in these disorders, but pharmacological treatment alone may not be sufficient. Patients should also be instructed to avoid specific allergens or environmental conditions that trigger their symptoms. Allergen-specific immunotherapy, parenteral administration of gradually increasing doses of the allergen ("allergy shots"), has been effective in allergic rhinitis, allergic conjunctivitis and allergic asthma, and also in prevention of anaphylaxis triggered by stings from bees, yellow jackets, hornets and wasps. It has not been effective in food allergy, atopic dermatitis or urticaria.
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
The Medical Letter on Drugs and Therapeutics • May 27, 2002; (Issue 1131)
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in...
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years old.